Recurrence-Free Survival in Patients With Surgically Resected Non-Small Cell Lung Cancer

Rajaram, Ravi; Huang, Qing; Li, Richard Z.; Chandran, Urmila; Zhang, Yuxin; Amos, Tony B.; Wright, George W.J.; Ferko, Nicole C.; Kalsekar, Iftekhar

doi:10.1016/j.chest.2023.11.042

Cited by 5 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-small-cell lung cancer (NSCLC) treatment encompasses various therapeutic approaches, including surgery, radiotherapy, chemotherapy, and targeted therapies, each with a distinct impact on tumor inflammation and cellular infiltration [ 3 ]. Surgical resection reduces tumor mass and decreases the inflammatory burden, potentially enhancing immune response [ 4 , 5 ]. Radiotherapy induces an inflammatory response that recruits immune cells, possibly boosting anti-tumor immunity but also causing collateral tissue damage [ 4 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Exploring Inflammatory Parameters in Lung Cancer Patients: A Retrospective Analysis

Feier,

Muntean,

Faur

et al. 2024

JPM

View full text Add to dashboard Cite

Inflammation-related parameters serve as pivotal indicators in the prognosis and management of lung cancer. This retrospective investigation aimed to explore the relationship between inflammatory markers and diverse clinical variables in non-small-cell lung cancer patients. A cohort of 187 individuals undergoing elective lobectomy for lung cancer was retrospectively analyzed, spanning an 11-year data collection period. Six inflammation ratios derived from complete peripheral blood counts were assessed. Significantly elevated levels of neutrophil-to-lymphocyte ratio (NLR) (p = 0.005), platelet-to-lymphocyte ratio (PLR) (p = 0.001), Aggregate Index of Systemic Inflammation (AISI) (p = 0.015), Systemic Inflammation Response Index (SIRI) (p = 0.004), and Systemic Immune Inflammation Index (SII) (p = 0.004) were observed in patients with advanced T stages. Significantly, elevated values (p < 0.05) of these parameters were observed in the study’s smoker patients compared to non-smokers. A statistically significant correlation was identified between the NLR parameter and tumor size (p = 0.07, r = 0.204), alongside a significant elevation in SIRI (p = 0.041) among patients experiencing postoperative complications. Inflammatory biomarkers emerge as invaluable prognostic indicators for patients with non-small-cell lung cancer, offering potential utility in forecasting their prognosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Exploring Inflammatory Parameters in Lung Cancer Patients: A Retrospective Analysis

Feier,

Muntean,

Faur

et al. 2024

JPM

View full text Add to dashboard Cite

show abstract

High circulating activin A plasma levels are associated with tumour stage and poor survival in treatment-naive lung squamous cell cancer patients

Sinn,

Elbeialy,

Mosleh

et al. 2025

Translational Oncology

View full text Add to dashboard Cite

Association between forced expiratory volume in 1 s and relapse-free survival in operable non-small cell lung cancer: a prospective cohort study with propensity score overlap weighting

Wu,

Fu,

Ripley-Gonzalez

et al. 2024

BMJ Open

View full text Add to dashboard Cite

ObjectivesInvestigate the correlation between the percentage of predicted forced expiratory volume in 1 s (FEV1%pred) and survival outcomes, namely relapse-free survival (RFS) and overall survival (OS), in patients diagnosed with operable early-stage non-small cell lung cancer (NSCLC).DesignProspective observational study.SettingClinical settings in Xiangya Hospital, Central South University, Hunan, China.ParticipantsFrom November 2014 to December 2019, 775 operable patients with NSCLC, median age 58 years (IQR 13) with 40.6% women, were consecutively enrolled and underwent preoperative FEV1 assessment. All participants were evaluated using the FEV1%pred assessment. Subsequent treatments and operative interventions followed established protocols for NSCLC.ResultsDuring the follow-up, which lasted a median of 40 months (range 1–85 months) and continued until December 2021, 202 patients either relapsed or died. Optimal FEV1%pred cut-off was identified using receiver operating characteristic analysis. Results revealed 110 and 71 relapses and deaths per 1000 person-years for patients with FEV1 values of <82%pred and ≥82%pred, respectively. Cox proportional hazards models, adjusted for demographics, medical history and surgery characteristics with propensity score overlap weighting, revealed the significant impact of lower FEV1%pred on decreased RFS and OS. An FEV1%pred less than 82% displayed a significant association with decreased RFS (weighted HR, 1.55; 95% CI, 1.14 to 2.09; p=0.007) and OS (weighted HR, 1.50; 95% CI, 1.01 to 2.23; p=0.04).ConclusionsLower FEV1%pred values notably correlate with compromised RFS and OS in individuals operable for early-stage NSCLC, suggesting that FEV1%pred may serve as a valuable tool in evaluating and managing long-term recurrence risk in patients with early-stage NSCLC.Trial registration numberChiCTR2100048120.

show abstract

Recurrence-Free Survival in Patients With Surgically Resected Non-Small Cell Lung Cancer

Cited by 5 publications

References 34 publications

Exploring Inflammatory Parameters in Lung Cancer Patients: A Retrospective Analysis

Exploring Inflammatory Parameters in Lung Cancer Patients: A Retrospective Analysis

High circulating activin A plasma levels are associated with tumour stage and poor survival in treatment-naive lung squamous cell cancer patients

Association between forced expiratory volume in 1 s and relapse-free survival in operable non-small cell lung cancer: a prospective cohort study with propensity score overlap weighting

Contact Info

Product

Resources

About